<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087282</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000373877</org_study_id>
    <secondary_id>MSKCC-04038</secondary_id>
    <secondary_id>NCI-6475</secondary_id>
    <nct_id>NCT00087282</nct_id>
  </id_info>
  <brief_title>Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer</brief_title>
  <official_title>A Non-Randomized Phase II Study of Sequential Irinotecan (CPT-11) And Flavopiridol In Patients With Advanced Hepatoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan and flavopiridol, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Combining more than one&#xD;
      drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving irinotecan together with&#xD;
      flavopiridol works in treating patients with advanced liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the time to progression in patients with advanced hepatocellular carcinoma&#xD;
           treated with irinotecan and flavopiridol.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate and overall survival in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized study.&#xD;
&#xD;
      Patients receive irinotecan IV over 30 minutes and flavopiridol IV over 1 hour on days 1, 8,&#xD;
      15, and 22. Courses repeat every 42 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 16-32 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed hepatocellular carcinoma&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  Prior local therapy (e.g., surgery, hepatic arterial embolization, radiofrequency&#xD;
             ablation, or cryoablation) allowed provided therapy was completed ≥ 8 weeks before&#xD;
             study entry AND ≥ 1 of the following conditions are met:&#xD;
&#xD;
               -  Target lesion was not subjected to local therapy&#xD;
&#xD;
               -  25% increase in the size of target lesion within the field of prior local therapy&#xD;
&#xD;
                    -  Lesions treated with external beam radiotherapy are not acceptable as target&#xD;
                       lesions&#xD;
&#xD;
          -  Child-Pugh class A or B status if liver cirrhosis is present&#xD;
&#xD;
               -  Score 7 or 8 only&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No deep vein thrombosis within the past 6 months&#xD;
&#xD;
               -  Patients maintained on anticoagulation therapy for an event that occurred more&#xD;
                  than 6 months ago are eligible&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No cardiac arrhythmia within the past 6 months&#xD;
&#xD;
               -  Rate-controlled atrial fibrillation allowed if stable for at least 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary embolus within the past 6 months&#xD;
&#xD;
               -  Patients maintained on anticoagulation therapy for an event that occurred more&#xD;
                  than 6 months ago are eligible&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to flavopiridol or irinotecan&#xD;
&#xD;
          -  No clinically significant gastrointestinal bleeding requiring hospitalization within&#xD;
             the past month&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No other malignancy within the past 3 years except carcinoma in situ of the cervix,&#xD;
             adequately treated basal cell skin cancer, or superficial bladder tumors [Ta, Tis, or&#xD;
             T1]&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior systemic biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior systemic chemotherapy for hepatocellular carcinoma&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent vitamins, antioxidants, or herbal preparations and supplements&#xD;
&#xD;
               -  Single-tablet multivitamin allowed&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghassan Abou-Alfa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary K. Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

